230000002489 hematologic Effects 0.000 claims description 4.239000008194 pharmaceutical composition Substances 0.000 claims description 5.206010035226 Plasma cell myeloma Diseases 0.000 claims description 5.206010025310 Other lymphomas Diseases 0.000 claims description 8.230000003834 intracellular Effects 0.000 claims description 17.150000001413 amino acids Chemical class 0.000 claims description 27.125000003275 alpha amino acid group Chemical group 0.000 claims description 46.150000007523 nucleic acids Chemical group 0.000 claims description 79.208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims description 84.206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims description 85.229920001850 Nucleic acid sequence Polymers 0.000 claims description 92.230000000139 costimulatory Effects 0.000 claims abstract description 46.230000027455 binding Effects 0.000 claims abstract description 92.230000011664 signaling Effects 0.000 claims abstract description 134.108010019670 Chimeric Antigen Receptors Proteins 0.000 claims abstract description 305.201000011510 cancer Diseases 0.000 title claims abstract description 65.108091007172 antigens Proteins 0.000 title claims abstract description 166.
102000038129 antigens Human genes 0.000 title claims abstract description 166.239000000427 antigen Substances 0.000 title claims abstract description 170.Priority to AU2020200767A priority patent/AU2020200767B2/en Priority to AU2022201895A priority patent/AU2022201895A1/en Status Active legal-status Critical Current Adjusted expiration legal-status Critical Links Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Family has litigation Priority claimed from US42147010P external-priority Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn Priority to AU2017203087A priority Critical patent/AU2017203087B2/en Publication of AU2017203087A1 publication Critical patent/AU2017203087A1/en Priority to AU2017225161A priority patent/AU2017225161C1/en Application granted granted Critical Publication of AU2017203087B2 publication Critical patent/AU2017203087B2/en First worldwide family litigation filed litigation Critical (B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License. Original Assignee University of Pennsylvania Penn Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Porter Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Active, expires Application number AU2017203087A Other versions AU2017203087A1 Google Patents AU2017203087B2 - Use of chimeric antigen receptor-modified t cells to treat cancer AU2017203087B2 - Use of chimeric antigen receptor-modified t cells to treat cancer
0 kommentar(er)
